EP Patent

EP1382331A1 — A pharmaceutical tablet characterized by a showing high volume increase when coming into contact with biological fluids

Assigned to Jagotec AG · Expires 2004-01-21 · 22y expired

What this patent protects

A description is given of a pharmaceutical form for oral administration consisting of a two- or three-layers tablet, wherein at least one layer can rapidly swell by contact with biological and/or aqueous fluids, said swelling resulting in a considerable increase in the tablet vo…

USPTO Abstract

A description is given of a pharmaceutical form for oral administration consisting of a two- or three-layers tablet, wherein at least one layer can rapidly swell by contact with biological and/or aqueous fluids, said swelling resulting in a considerable increase in the tablet volume. Said phenomenon determines a prolonged residence of the pharmaceutical form at the gastric level and therefore allows a slow release of the active ingredient from said pharmaceutical form to the stomach and/or the first tract of the intestine.

Drugs covered by this patent

Patent Metadata

Patent number
EP1382331A1
Jurisdiction
EP
Classification
—
Expires
2004-01-21
Drug substance claim
No
Drug product claim
No
Assignee
Jagotec AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.